Hormone Therapy News

A Dutch cohort of older transgender women prescribed long-term gender-affirming hormone therapy had a 3-year fracture risk that was comparable to that of cisgender women, according to findings published in the Journal of Bone and Mineral Research.

For women who had a hysterectomy and their ovaries removed, estrogen therapy was associated with long-term benefits if the therapy began before the age of 60 years, but it led to adverse events in those aged 70 years or older, according to a study published in the Annals of Internal Medicine.

A recent meta-analysis of nearly 60 epidemiologic studies suggests that women who initiated systemic hormone therapy around the time of menopause were at greater risk for invasive breast cancer than similar never-users, with some excess risk persisting more than a decade after stopping therapy. The analysis, which evaluated findings from large observational studies, also suggests that increased risk for breast cancer doubles for women who used hormone therapy for 10 years vs. 5 years.

A coalition of 11 leading medical societies worldwide released a global position statement outlining best practices for the use of testosterone for women, stating the therapy is appropriate for women with hypoactive sexual desire disorder/dysfunction but noting that evidence does not support such treatment for any other symptoms or medical conditions.

Endocrine Today has compiled a list of the top 10 news reports posted so far in of 2019.

Transgender men who become pregnant are at increased risk for depression and difficulty getting medical care due to a lack of knowledge among health care providers, according to a literature review published in Maturitas.

Each month Endocrine Today reporters delve deep into a topic of current interest. These longform cover stories provide background and insights from leading researchers and clinicians. All of these features can be found under the opinion tab above and at the links below. Stories published so far in 2019 include emerging alternatives in thyroid cancer treatment, promising developments in beta-cell regeneration, questions about vitamin D’s effectiveness, and more.

Women who initiated systemic hormone therapy around the time of menopause were at greater risk for invasive breast cancer than similar never-users, according to an analysis of nearly 60 epidemiologic studies published in The Lancet.

An estimated 40% to 50% of childhood cancer survivors will experience an endocrine disorder in their lifetime. The risk varies according to cancer treatment and can persist for decades after diagnosis.

Transdermal estradiol was an effective add-on treatment for women with schizophrenia, particularly those aged older than 38 years, findings published in JAMA Psychiatry showed.